Daptomycin vs. glycopeptides in the treatment of febrile neutropenia: results of the Izmir matched cohort study

dc.contributor.authorSipahi, Oguz Resat
dc.contributor.authorKahraman, Hasip
dc.contributor.authorErdem, Huseyin Aytac
dc.contributor.authorYetkin, Funda
dc.contributor.authorKaya, Selcuk
dc.contributor.authorDemirdal, Tuna
dc.contributor.authorTunccan, Ozlem Guzel
dc.contributor.authorKarasahin, Omer
dc.contributor.authorOruc, Ebru
dc.contributor.authorCag, Yasemin
dc.contributor.authorKurtaran, Behice
dc.contributor.authorUlug, Mehmet
dc.contributor.authorKutlu, Murat
dc.contributor.authorAvci, Meltem
dc.contributor.authorOztoprak, Nefise
dc.contributor.authorArda, Bilgin
dc.contributor.authorPullukcu, Husnu
dc.contributor.authorTasbakan, Meltem
dc.contributor.authorYamazhan, Tansu
dc.contributor.authorKandemir, Ozlem
dc.contributor.authorDizbay, Murat
dc.contributor.authorSipahi, Hilal
dc.contributor.authorUlusoy, Sercan
dc.date.accessioned2019-10-27T09:45:14Z
dc.date.available2019-10-27T09:45:14Z
dc.date.issued2019
dc.departmentEge Üniversitesien_US
dc.description.abstractPurposeIn this multicentre, retrospective, matched cohort study we aimed to evaluate the outcomes of neutropenic fever cases that were treated with daptomycin or a glycopeptide (vancomycin or teicoplanin).MethodsData and outcomes of adult (aged>18-years old) patients with neutropenic fever [(1) without clinical and radiological evidence of pneumonia, (2) who were treated with daptomycin or a glycopeptide (teicoplanin or vancomycin) for any reason and for at least 72 h] were extracted from the hospital databases. Matching was performed with all of the three following criteria: (1) underlying disease, (2) reason for starting daptomycin or glycopeptide (microbiologic evidence vs. microbiologic evidence, clinical infection vs. clinical infection and empirical therapy vs. empirical therapy) and (3) neutropenic status.ResultsOverall 128 patients [(69/123) (56.1%) in the daptomycin cohort (D) and 59/123 (48%) in the glycopeptide cohort (G)] had a resolution of fever at the end of 72h antibiotic treatment (p=0.25). There was no significant difference in cured, improved and (cured+improved) rates between (D) and (G) cohorts as well as fever of unknown origin cases or microbiologically confirmed infections or clinically defined infections subgroups (p>0.05). There was also no significant difference (p>0.05), in terms of persistent response in the (D) versus (G) cohorts,ConclusionsThese findings suggest that although not better, daptomycin efficacy is comparable to vancomycin if used as empiric therapy in the treatment of adult febrile neutropenia. We conclude that daptomycin may be used at least as a salvage therapy alternative to glycopeptides in the treatment of adult febrile neutropenia cases. A large, randomized-controlled trial may further consolidate the evidence related to this question.en_US
dc.identifier.doi10.1007/s15010-018-1256-8en_US
dc.identifier.endpage266en_US
dc.identifier.issn0300-8126
dc.identifier.issn1439-0973
dc.identifier.issue2en_US
dc.identifier.pmid30498901en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage259en_US
dc.identifier.urihttps://doi.org/10.1007/s15010-018-1256-8
dc.identifier.urihttps://hdl.handle.net/11454/29115
dc.identifier.volume47en_US
dc.identifier.wosWOS:000462946100012en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofInfectionen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectLipopeptidesen_US
dc.subjectNeutropenic feveren_US
dc.subjectBacteremiaen_US
dc.subjectEmpirical therapyen_US
dc.subjectLinezoliden_US
dc.titleDaptomycin vs. glycopeptides in the treatment of febrile neutropenia: results of the Izmir matched cohort studyen_US
dc.typeArticleen_US

Dosyalar